Table 5.
Grade 3 or 4 Everolimus-Adverse Events Occurred in Eligible Studies
| Lung Subgroup Analysis RADIANT-2 EVE Plus OCT LAR | Lung Subgroup Analysis RADIANT-4 EVE | ITMO EVE Plus OCT | ITMO 5-Year Update EVE Plus OCT | LUNA EVE | LUNA EVE Plus PAS | |
|---|---|---|---|---|---|---|
| Stomatitis | 23 (69.7%) | 7 (11.3%) | 5 (10%) | 4 (8%) | 4 (10%) | 2 (5%) |
| Rash | 11 (33.3%) | 0 | 1 (2%) | 1 (2%) | 3 (7%) | NR |
| Fatigue | 4 (12.1%) | 2 (3.2%) | NR | NR | 1 (2%) | 4 (10%) |
| Diarrhoea | 9 (27.3%) | 3 (4.8%) | 11 (22%) | 4 (8%) | 3 (7%) | 8 (19%) |
| Nausea | 4 (12.1%) | 2 (3.2%) | NR | NR | 1 (2%) | NR |
| Infections | NR | 5 (7.1%) | 1 (2%) | NR | NR | NR |
| Dysgeusia | 4 (12.1%) | 0 | NR | NR | 0 | NR |
| Anaemia | 5 (15.2%) | 2 (3.2%) | 1 (2%) | 1 (2%) | 1 (2%) | 2 (5%) |
| Leukopenia | 4 (12.1%) | NR | 1 (2%) | 1 (2%) | NR | NR |
| Decreased weight | 4 (12.1%) | 1 (1.6%) | NR | NR | 1 (2%) | 3 (7%) |
| Thrombocytopenia | 6 (18.2%) | NR | NR | NR | 1 (2%) | NR |
| Decreased appetite | 4 (12.1%) | 0 | NR | NR | 2 (5%) | 2 (5%) |
| Peripheral oedema | NR | 2 (3.2%) | NR | NR | 1 (2%) | 1 (2%) |
| Hyperglycaemia | 5 (15.2%) | 6 (9.8%) | NR | NR | 7 (17%) | 10 (24%) |
| Dyspnoea | 5 (15.2%) | 1 (1.6%) | NR | NR | 2 (5%) | 2 (5%) |
| Pulmonary events | NR | 1 (1. 6%) | NR | NR | 3 (7%) | 2 (5%) |
| Vomiting | NR | NR | NR | NR | NR | 1 (2%) |
| Pruritus | 4 (12.1%) | 1 (1.6%) | NR | NR | NR | NR |
| Asthenia | 8 (24.2%) | 1 (1.6%) | NR | NR | 1 (2%) | 1 (2%) |
| Erythema | 5 (15.2%) | NR | NR | NR | NR | NR |
| Pyrexia | NR | 2 (3.2%) | NR | NR | 1 (2%) | NR |
| Hypercholesterolemia | NR | NR | NR | 1 (2%) | NR | NR |
| Hypokalemia | NR | NR | NR | 4 (8%) | NR | NR |
| Hypertriglyceridemia | NR | NR | NR | 1 (2%) | NR | 1 (2%) |
| Hyponatremia | NR | NR | NR | 1 (2%) | NR | NR |
| Acute myocardial infarction | NR | NR | NR | 1 (2%) | NR | NR |
| Constipation | NR | NR | NR | NR | 1 (2%) | NR |
| Blood alkaline phosphatase increased | NR | NR | NR | NR | 1 (2%) | 1 (2%) |
| γ-glutamyltransferase increased | NR | NR | NR | NR | 3 (7%) | 3 (7%) |
| Hypophosphataemia | NR | NR | NR | NR | 2 (5%) | 1 (2%) |
| Mouth ulceration | NR | NR | NR | NR | 1 (2%) | 1 (2%) |
| Haemorrhoids | NR | NR | NR | NR | 1 (2%) | NR |
| Flushing | NR | NR | NR | NR | 1 (2%) | NR |
| Diabetes mellitus | NR | NR | NR | NR | NR | 3 (7%) |
| Chest pain | NR | NR | NR | NR | NR | 1 (2%) |
| Aspartate aminotransferase increased | NR | NR | NR | NR | NR | 1 (2%) |
| Dysphagia | NR | NR | NR | NR | 2 (5%) | NR |
| General physical health deterioration | NR | NR | NR | NR | 1 (2%) | NR |
| Pulmonary embolism | NR | NR | NR | NR | 1 (2%) | 2 (5%) |
Abbreviations: NR, not reported; OCT, octreotide; PAS, pasireotide.